EUVIMEDOpdag EUVIMED
Crossref

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors

Hyun-Kyung Ko, Rebecca L Foertsch, Kasen Shi, Janét Pittsenbarger, Changhui Xue, Kaiyo Shi, Hao Geng, Lina Gao iD, David Z Qian

The Prostate · 2026-03 · 86 (4) · 428-439

DOI: 10.1002/pros.70100 ↗

At a glance

Journal article in The Prostate, published online on 2025-12-09. Written by Hyun-Kyung Ko and 8 co-authors. Institution: Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. Major MEDLINE topics: Receptors, Androgen, Epithelial-Mesenchymal Transition, NAD, Prostatic Neoplasms. Cited 2 times so far (Crossref); 48 references. Funded by: OHSU Prostate Cancer Program and NIH.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Metastatic prostate cancers are primarily treated by therapies targeting the androgen/androgen receptor (AR) signaling pathways. Despite the initial success, treatment resistance is almost universal, leading to disease progression and patient mortality. Currently, the molecular mechanism and vulnerability of treatment‐resistant prostate cancers are poorly understood. These knowledge gaps are major obstacles in improving treatment and patient survival. Recently, we used the single‐cell approach to establish a new anti‐androgen/AR resistant cell model, in which tumor cells had an AR‐low phenotype, expressing low levels of AR and AR‐target genes, and were resistant to androgen‐deprivation (ADT) and enzalutamide in vitro and in vivo.

Methods

We determined the transcriptome of the treatment‐resistant AR‐low cells with bulk RNA‐Seq, qRT‐PCR, and chromatin immunoprecipitation (ChIP)‐qPCR. We identified a metabolic vulnerability of the resistant cells with siRNA, plasmid‐based overexpression and metabolic assays. We next determined whether the vulnerability can be exploited by small molecule inhibitors to enhance enzalutamide with proliferation and colony formation assays and Incucyte‐based live cell imaging. We also determined the clinical relevance of the vulnerability with the prostate cancer TCGA data set.

Results

The AR‐low treatment resistant tumor cells had significantly different transcriptomes from the treatment‐sensitive counterparts, notably represented by the EMT‐high expression phenotype. The resistant cells were deficient in the expression of NAPRT, a rate determining enzyme in nicotinamide adenine dinucleotide (NAD+) biosynthesis, causing the resistant cells to be vulnerable to NAD+ biosynthesis inhibitors. Importantly, this vulnerability can be exploited to enhance enzalutamide efficacy in the castration sensitive setting as NAPRT‐low was phenotypically associated with EMT‐high and AR‐low in subpopulations of tumor cells and patient samples.

Conclusion

Our newly established treatment‐resistant cell model has the AR‐low/EMT‐high phenotype, which is clinically associated with enzalutamide resistance in patients. NAPRT‐deficiency (NAPRT‐low) can be a novel vulnerability associated with the AR‐low/EMT‐high phenotype and thus can be targeted by NAD+ inhibitors to improve enzalutamide efficacy.

Subjects

MeSH terms (MEDLINE)

Receptors, AndrogenEpithelial-Mesenchymal TransitionNADProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantMaleHumansBenzamidesNitrilesCell Line, TumorPhenylthiohydantoinPhenotypeDrug Resistance, NeoplasmAnimalsMice

Author keywords

AR‐lowNAD+ biosynthesis inhibitorsenzalutamide resistancevulnerability

Substances

Receptors, AndrogenBenzamidesNitrilesenzalutamidePhenylthiohydantoinNADAR protein, human

Authors and institutions

  • Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Biostatistics Core, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.

ORCID profiles: Lina Gao

Funding

  • OHSU Prostate Cancer Program and NIH

Cite

APA

Ko, H. K., Foertsch, R. L., Shi, K., Pittsenbarger, J., Xue, C., Shi, K., Geng, H., Gao, L., & Qian, D. Z. (2026). Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors. The Prostate, 86(4), 428-439. https://doi.org/10.1002/pros.70100

Vancouver

Ko HK, Foertsch RL, Shi K, Pittsenbarger J, Xue C, Shi K, et al. Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors. The Prostate. 2026;86(4):428-439. doi:10.1002/pros.70100

BibTeX
@article{Ko2026,
  author = {Ko, Hyun-Kyung and Foertsch, Rebecca L and Shi, Kasen and Pittsenbarger, Janét and Xue, Changhui and Shi, Kaiyo and Geng, Hao and Gao, Lina and Qian, David Z},
  title = {Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {4},
  pages = {428--439},
  doi = {10.1002/pros.70100}
}
Start for free →